Celgene diversifies portfolio with purchase of Juno Therapeutics
January 22, 2018 at 10:10 AM EST
Earlier this month, Celgene announced that it was taking over Impact Biomedicines in a $7 billion transaction.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|